Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
Fulcrum Therapeutics to Participate in Upcoming December Conferences
04:05pm, Tuesday, 26'th Nov 2024
CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
07:48pm, Wednesday, 13'th Nov 2024
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Finan
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
04:05pm, Tuesday, 12'th Nov 2024
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to i
New Strong Buy Stocks for November 12th
07:40am, Tuesday, 12'th Nov 2024
GGAL, GFI, FULC, DECK and NGD have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2024.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
10:56am, Friday, 25'th Oct 2024
FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) con
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) con
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 11'th Oct 2024
CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) con
Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - FULC
07:25am, Thursday, 10'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) con
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
12:37pm, Wednesday, 09'th Oct 2024
Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
07:30am, Wednesday, 09'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) conc
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) conc
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
02:03pm, Monday, 07'th Oct 2024
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmace
